A meta-analysis of the gene expression data sets revealed that BLM levels were significantly upregulated in a subset of poorly differentiated CRC samples wherein shorter relapse-free survival was seen (Votino et al., 2017). The gene discussed is BLM; the disease is colorectal carcinoma.